The Indonesian Food and Drug Authority (BPOM) and Singapore’s Health Sciences Authority (HSA) have initiated a partnership to conduct joint assessments of complementary health products. This collaboration aims to streamline regulatory processes and enhance product evaluation standards between the two agencies.
In related news, China has approved new joint health claims for certain products, marking a significant development in the country’s regulatory landscape. These approvals may influence market access and labeling practices for health-related products in China.
**Why this matters**
The BPOM-HSA collaboration could lead to faster regulatory reviews and greater alignment in safety and efficacy standards for complementary health products in Southeast Asia. Meanwhile, China’s approval of joint health claims may set new precedents for product marketing and consumer information, impacting manufacturers and regulators in the region.